COCRYSTAL PHARMA, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
COCRYSTAL PHARMA, INC. (COCP) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-31
- COCRYSTAL PHARMA, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was 0.00%.
- COCRYSTAL PHARMA, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -3.78%.
- COCRYSTAL PHARMA, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -2.10%, a 1150.00% decline from fiscal 2022.
- COCRYSTAL PHARMA, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 0.20%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-31 | |
| 2024-12-31 | -3.78% 10-K · filed 2026-03-31 | -3.80% 10-K · filed 2025-03-31 |
| 2023-12-31 | -2.10% 10-K · filed 2025-03-31 | -1.50% 10-K · filed 2024-03-28 |
| 2022-12-31 | 0.20% 10-K · filed 2024-03-28 | |
| 2021-12-31 | -0.60% 10-K · filed 2023-03-29 | 1.30% 10-K · filed 2022-03-23 |
| 2020-12-31 | 1.50% 10-K · filed 2022-03-23 | |
| 2019-12-31 | -4.00% 10-K · filed 2021-03-17 | |
| 2018-12-31 | -3.80% 10-K · filed 2020-03-27 | 0.10% 10-K · filed 2019-04-01 |
| 2017-12-31 | 1.20% 10-K · filed 2019-04-01 | |
| 2015-12-31 | -0.80% 10-K · filed 2018-03-21 | |
| 2014-12-31 | -0.70% 10-K · filed 2017-03-31 | -70.00% 10-K · filed 2015-03-31 |
| 2013-12-31 | 69.00% 10-K · filed 2014-03-31 | |
| 2012-12-31 | 67.00% 10-K · filed 2014-03-31 | |
| 2011-12-31 | 16.00% 10-K · filed 2013-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |